April 30, 2019 (Madison, WI): Nimble Therapeutics has begun operating as a standalone business after spinning out from F. Hoffmann La Roche (SIX: RO, ROG;

GUILFORD, CONN. AND WALNUT CREEK, CALIF. (PRWEB) APRIL 22, 2019 Medpricer, the leading purchased services cost management solution for the healthcare industry, announced today Intermountain Healthcare

Vancouver, British Columbia– Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines used in oncology, rare disease and infectious

MENLO PARK, Calif.–Akoya Biosciences, Inc., today announced the appointment of Joseph Driscoll as Chief Financial Officer. Mr. Driscoll joins Akoya with more than 30 years

Austin, Texas — 04/02/2019 — Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, today announced a substantial

The Horizon ® system was designed to offer more versatility in one system, and more treatment options for patients.  This clearance allows Magstim to market the 3-minute

Seattle, WA, March 28, 2019 – RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting

March 20, 2019 – Guilford, CT/Walnut Creek, CA – Medpricer, the leading purchased services cost management solution for the healthcare industry, announced today the launch of

Cardiff, UK, and Baltimore, U.S., January 29, 2018 – TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, and

MENLO PARK–(BUSINESS WIRE)—October 31, 2018—Akoya Biosciences (Akoya), a Telegraph Hill Partners (THP) company, has acquired PerkinElmer, Inc’s Quantitative Pathology Solutions (QPS) portfolio.  Akoya was founded

SAN DIEGO, Calif., and GUANGZHOU, China, Wednesday, October 24, 2018 – Agena Bioscience (Agena) and DaRui Biotechnology (DaRui) announced today that the MassARRAY System has

The panel accurately and sensitively detects over 1600 variants of clinical significance AUSTIN, Texas — Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to